Zobrazeno 1 - 10
of 41
pro vyhledávání: '"Durrbach, A."'
Autor:
Marie Courbebaisse, Aurelie Bourmaud, Jean-Claude Souberbielle, Rebecca Sberro-Soussan, Valérie Moal, Yannick Le Meur, Nassim Kamar, Laetitia Albano, Antoine Thierry, Jacques Dantal, Clément Danthu, Karine Moreau, Emmanuel Morelon, Anne-Elisabeth Heng, Dominique Bertrand, Nadia Arzouk, Peggy Perrin, Marie-Pascale Morin, Philippe Rieu, Claire Presne, Philippe Grimbert, Didier Ducloux, Matthias Büchler, Moglie Le Quintrec, Nacéra Ouali, Vincent Pernin, Nicolas Bouvier, Antoine Durrbach, Eric Alamartine, Christine Randoux, Virginie Besson, Marc Hazzan, Justine Pages, Sandra Colas, Marie-Liesse Piketty, Gérard Friedlander, Dominique Prié, Corinne Alberti, Eric Thervet
Publikováno v:
American Journal of Transplantation. 23:366-376
Autor:
Hannah Kaminski, Nassim Kamar, Olivier Thaunat, Nicolas Bouvier, Sophie Caillard, Isabelle Garrigue, Dany Anglicheau, Jean-Philippe Rérolle, Yannick Le Meur, Antoine Durrbach, Thomas Bachelet, Hélène Savel, Roxane Coueron, Jonathan Visentin, Arnaud Del Bello, Isabelle Pellegrin, Julie Déchanet-Merville, Pierre Merville, Rodolphe Thiébaut, Lionel Couzi
Publikováno v:
American Journal of Transplantation
American Journal of Transplantation, 2022, ⟨10.1111/ajt.16946⟩
American Journal of Transplantation, 2022, ⟨10.1111/ajt.16946⟩
International audience; Cytomegalovirus (CMV) persists as the most frequent opportunistic infection among solid organ transplant recipients. This multicenter trial aimed to test whether treatment with everolimus (EVR) could decrease the incidence of
Autor:
Karen Bargiel, Florence Herr, Bernard Vanhove, Christophe Desterke, Manon Dekeyser, Antoine Durrbach, Fan Ye, Radu Vadanici, Amelia Vernochet
Publikováno v:
American Journal of Transplantation. 22:489-503
Belatacept was developed to replace calcineurin inhibitors in kidney transplantation. Its use is associated with better kidney transplant function, a lower incidence of anti-donor antibodies and higher graft survival. However, it is also associated w
Autor:
Andrew B. Adams, David Wojciechowski, Allan D. Kirk, E. Steve Woodle, David A. Hildeman, Christian P. Larsen, Antoine Durrbach, Mandy L. Ford, Flavio Vincenti
Publikováno v:
American Journal of Transplantation
Kidney transplant recipients administered belatacept‐based maintenance immunosuppression present with a more favorable metabolic profile, reduced incidence of de novo donor‐specific antibodies (DSAs), and improved renal function and long‐term p
Autor:
Antoine Durrbach, Marie-Ghislaine de Goër de Herve, Fathia Mami-Chouaib, Stéphanie Corgnac, Yassine Taoufik
Publikováno v:
Frontiers in Immunology
Frontiers in Immunology, Vol 12 (2021)
Frontiers in Immunology, Vol 12 (2021)
Since its emergence at the end of 2019, SARS-CoV-2 has spread worldwide at a very rapid pace. While most infected individuals have an asymptomatic or mild disease, a minority, mainly the elderly, develop a severe disease that may lead to a fatal acut
Autor:
Nathalie Chavarot, Bruno Moulin, Valérie Moal, Olivier Thaunat, Marc Hazzan, Jamal Bamoulid, Antoine Durrbach, Christiane Mousson, Nassim Kamar, Yannick Lemeur, Charlotte Kaeuffer, Clarisse Greze, Philippe Grimbert, Ilies Benotmane, Dominique Bertrand, Antoine Thierry, Tristan Legris, Gilles Blancho, Pierre François Westeel, Mariam Jdidou, Hélène François, Sophie Caillard, Marie Matignon, Yvon Ruch, Morgane Solis, Antoine Sicard, Dany Anglicheau, Philippe Gatault, Valentin Goutaudier, François Danion, Lionel Couzi, Charlotte Colosio, Renaud Snanoudj, Christophe Masset, Agnès Duveau, Jonathan M. Chemouny, Luc Frimat
Publikováno v:
American Journal of Transplantation
American Journal of Transplantation, 2021, 21 (3), pp.1295-1303. ⟨10.1111/ajt.16424⟩
American Journal of Transplantation, Wiley, 2021, 21 (3), pp.1295-1303. ⟨10.1111/ajt.16424⟩
American Journal of Transplantation, Wiley, 2020, ⟨10.1111/ajt.16424⟩
American Journal of Transplantation, 2021, 21 (3), pp.1295-1303. ⟨10.1111/ajt.16424⟩
American Journal of Transplantation, Wiley, 2021, 21 (3), pp.1295-1303. ⟨10.1111/ajt.16424⟩
American Journal of Transplantation, Wiley, 2020, ⟨10.1111/ajt.16424⟩
International audience; There are no studies which have compared the risk of severe Covid-19 and related mortality between transplant recipients and non-transplant patients. We enrolled two groups of patients hospitalized for Covid-19, i.e., kidney t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::be9ea1ec322955571bb6d6cd2410be7e
https://ut3-toulouseinp.hal.science/hal-03371189/document
https://ut3-toulouseinp.hal.science/hal-03371189/document
Publikováno v:
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant SurgeonsREFERENCES. 20(9)
Solid organ transplant (SOT) is frequently complicated by cancers, which render immunosuppression challenging. Immune checkpoint inhibitors have emerged as treatments for many cancers. Data are lacking regarding efficacy and rejection risk in the SOT
Autor:
J. Grinyo, Martin Polinsky, Gilles Blancho, Flavio Vincenti, H. U. Meier-Kriesche, L. Yang, G. Grannas, Christian P. Larsen, Antoine Durrbach
Publikováno v:
American Journal of Transplantation
In the phase II IM103‐100 study, kidney transplant recipients were first randomized to belatacept more‐intensive‐based (n = 74), belatacept less‐intensive‐based (n = 71), or cyclosporine‐based (n = 73) immunosuppression. At 3‐6 months p
Autor:
Laurent Salomon, Stéphanie Malard, Thomas Robert, Caroline Pilon, Emmanuelle Boutin, Florence Canoui-Poitrine, Antoine Durrbach, Marie Matignon, Anissa Zarour, Claire Leibler, Anissa Moktefi, Philippe Grimbert, Chloé Samson, Pierre-André Natella
Publikováno v:
American Journal of Transplantation
American Journal of Transplantation, 2019, 19 (3), pp.894-906. ⟨10.1111/ajt.15229⟩
American Journal of Transplantation, 2019, 19 (3), pp.894-906. ⟨10.1111/ajt.15229⟩
The benefit of belatacept on antibody-mediated rejection (ABMR) incidence after kidney transplant with preformed donor-specific antibodies (DSAs) has never been assessed. Between 2014 and 2016, we conducted a multicenter prospective clinical trial wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e8da20b2ba22596ac066cfae788b14f3
https://hal.u-pec.fr/hal-04156070
https://hal.u-pec.fr/hal-04156070
Autor:
Thomas Wekerle, Lionel Rostaing, J. Grinyo, Martin Polinsky, José Osmar Medina Pestana, Arthur J. Matas, Dirk Kuypers, Antoine Durrbach, M. del Carmen Rial, H. U. Meier-Kriesche, Sander Florman, S. Munier
Publikováno v:
American Journal of Transplantation
In the Belatacept Evaluation of Nephroprotection and Efficacy as First‐Line Immunosuppression Trial–Extended Criteria Donors (BENEFIT‐EXT), extended criteria donor kidney recipients were randomized to receive belatacept‐based (more intense [M